Lin BioScience, Inc.
6696
Rank in Stocks
#3771
Lin BioScience, Inc. is an innovative biopharmaceutical company focused on... Lin BioScience, Inc. is an innovative biopharmaceutical company focused on developing novel therapies across oncology, ophthalmology, and metabolic diseases. Its robust pipeline includes LBS-008, an orally administered treatment currently in Phase 3 clinical trials for adolescent Stargardt disease (STGD1) and Phase 2/3 trials for dry age-related macular degeneration (Dry AMD), both aimed at evaluating its safety and effectiveness. Other key candidates are LBS-007, a natural non-ATP CDC7 inhibitor designed to combat various cancers; LBS-002, an anti-tubulin compound targeting primary and metastatic brain tumors; and LBS-009, an oral medication for non-alcoholic fatty liver disease and Type 2 diabetes. The company is headquartered in Taipei, Taiwan.
Share Price
$5.34
Market Cap
$4.43B
Change (1 day)
3.07%
Change (1 year)
-39.48%
Country
TW
Trade Lin BioScience, Inc. (6696)
Category
Healthcare
Stock split history for Lin BioScience, Inc. (6696)
Lin BioScience, Inc. stock (symbol: 6696) underwent a total of 0 stock splits.
The most recent stock split occurred on Oct 21, 2026.
One 6696 share bought prior to Oct 21, 2026 would equal to 0 6696 shares today.
The most recent stock split occurred on Oct 21, 2026.
One 6696 share bought prior to Oct 21, 2026 would equal to 0 6696 shares today.
Stock split list
| Year | Split | Multiple | Cumulative Multiple |
|---|---|---|---|
| Not enough data for the provided dates. | |||
Stock splits for similar companies or competitors
| Company | Number of stock splits | Cumulative Multiple | Country |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
NL
|
|
| 0 | - |
CH
|
